The DOI matches its Crossref record; 107 of the 116 references it cites were found in a registry or an index.
SALL4: An Intriguing Therapeutic Target in Cancer Treatment
Open accessAbstract
Spalt-Like Transcription Factor 4 (SALL4) is a critical factor for self-renewal ability and pluripotency of stem cells. On the other hand, various reports show tight relation of SALL4 to cancer occurrence and metastasis. SALL4 exerts its effects not only by inducing gene expression but also repressing a large cluster of genes through interaction with various epigenetic modifiers. Due to high expression of SALL4 in cancer cells and its silence in almost all adult tissues, it is an ideal target for cancer therapy. However, targeting SALL4 meets various challenges. SALL4 is a transcription factor and designing appropriate drug to inhibit this intra-nucleus component is challenging. On the other hand, due to lack of our knowledge on structure of the protein and the suitable active sites, it becomes more difficult to reach the appropriate drugs against SALL4. In this review, we have focused on approaches applied yet to target this oncogene and discuss the potential of degrader systems as new therapeutics to target oncogenes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a transcription factor, the uniqueness of SALL4 lies in the fact that it is expressed in embryonic cells, downregulated during development, absent in most adult tissues, and re-expressed in a significant fraction of almost all human adult tumors (Moein et al, 2022; Tatetsu et al, 2016).”
From Targeting transcription factors through an IMiD independent zinc finger domain (2025) · cites this paper as Moein et al, 2022
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a transcription factor, the uniqueness of SALL4 lies in the fact that it is expressed in embryonic cells, downregulated during development, absent in most adult tissues, and re-expressed in a significant fraction of almost all human adult tumors (Moein et al, 2022; Tatetsu et al, 2016).”
From Targeting transcription factors through an IMiD independent zinc finger domain (2025) · cites this paper as Moein et al, 2022
The cited source says what the claim attributes to it.
In the citing paper
“there is some evidence that it may act as an oncogene 68”
From Tetramerisation governs SALL transcription factor function in development and disease (2025) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4
Zhou, W., Zou, B., Liu, L., Cui, K., Gao, J., Yuan, S., & Cong, N. (2016) · Oncotarget · doi:10.18632/oncotarget.12190 · Cited by 59
RetractedXia, Z., Qiu, D., Deng, J., Jiao, X., Yang, R., Sun, Z., Wan, X. H., & Li, J. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3464 · Cited by 12
RetractedVillanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G., & Galluzzi, L. (2018) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,273 · cited 1×
“Oligomycin is a macrolide produced by Streptomyces and an inhibitor of adenosine triphosphate (ATP) synthase [90].”
BackgroundDefining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537 · cited 4×
“Thalidomide as an ImiD, promotes ubiquitination and subsequent degradation of SALL4A on ZFC2 C2H2 domains by binding to Cereblon (CRBN) in the choline complex E3 ubiquitin ligase Cells 2022, 11, 2601 11 of 15 (CRL4CRBN) [105].”
BackgroundInfluentialDonovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509
The LIN28/let-7 Pathway in Cancer
Balzeau, J., Menezes, M. R., Cao, S., & Hagan, J. P. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00031 · Cited by 447
The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells.
Dimri, G. P., Martínez‐Guitarte, J., Jacobs, J. J. L., Keblusek, P., Itahana, K., van Lohuizen, M., Campisi, J., Wazer, D. E., & Band, V. (2002) · PubMed · Cited by 396
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Qi, S.-M., Dong, J., Xu, Z.-Y., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 292 · cited 1×
“For a while, lack of structure knowledge on suitable active or binding sites, localization of the protein in the nucleus, and inaccessibility on the cell surface all make SALL4 as a critical choice for therapeutic drug design [86].”
BackgroundOncofetal Gene SALL4 in Aggressive Hepatocellular Carcinoma
Yong, K. J., Gao, C., Lim, J. S. J., Yan, B., Yang, H., Dimitrov, T., Kawasaki, A., Ong, C. W., Wong, K.-F., Lee, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300297 · Cited by 257 · cited 4×
“The prognostic value of SALL4 in primary HCC also is determined in our previous study [58].”
BackgroundResultSelf-citation
Cited by
Steinebach, C., Bricelj, A., Murgai, A., Sosič, I., Bischof, L., Ng, Y. L. D., Heim, C., Maiwald, S. A., Proj, M., Voget, R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00851 · Cited by 60
Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy
Wang, W., Liu, W., Chen, Q., Yuan, Y., & Wang, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.002 · Cited by 51
Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma
Liu, J., Park, K., Shen, Z., Lee, H. M., Geetha, P., Pakyari, M., & Chai, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285370 · Cited by 25
“Another promising TF target is SALL4, a TF involved in cell renewal and growth during development (124).”
BackgroundSelf-citationRole of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
Pattanayak, B., Lameirinhas, A., Torres‐Ruiz, S., Burgués, O., Rovira, A., Martínez, M. T., Tapia, M., Zazo, S., Albanell, J., Rojo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113292 · Cited by 16
Cancer stem cell biomarkers and related signalling pathways
Wang, Z., Li, R. Q., Yang, G., & Wang, Y. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2295222 · Cited by 15
“the human homolog of the Drosophila salt (sal) homeostasis gene, SAll4, encodes a c2H2 zinc finger transcription factor (tF) [93].”
Background
Metadata
- Authors
- Moein, S., Tenen, D. G., Amabile, G., & Chai, L.
- Affiliations
- Cancer Science Institute of Singapore (SG)
- Harvard University (US)
- Believer Pharmaceuticals, Inc., Wilmington, DE 19801, USA
- Brigham and Women's Hospital (US)
- Corresponding author
- Tenen, Daniel G.
- Amabile, Giovanni
- Chai, Li
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-08-20
- Volume
- 11
- Issue
- 16
- Pages
- 2601
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9406946
- OpenAlex
- W4292549048
- Cited by
- 35
- References
- 116
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 9 · 2023: 7 · 2022: 3
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Health (R35CA197697, P01HL131477-01A1, STaR18nov-0002)
- NIH/NHLBI (R35CA197697, P01HL131477-01A1, STaR18nov-0002)
- Singapore Ministry of Health’s National Medical Research Council (Singapore Translational Research (STaR) Investigator Award) (R35CA197697, P01HL131477-01A1, STaR18nov-0002)
- Xiu research fund (R35CA197697, P01HL131477-01A1, STaR18nov-0002)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- SALL4, oncogenes, cancer therapy, therapeutic target, transcription factors, epigenetic regulation, gene repression, stem cell pluripotency, metastasis, drug design
- MeSH terms
- Adult, Gene Expression Regulation, Humans, Neoplasms, Stem Cells, Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SALL4: An Intriguing Therapeutic Target in Cancer Treatment. https://app.cochat.ai/papers/10.3390/cells11162601
- The paper
- Moein, S., Tenen, D. G., Amabile, G., & Chai, L. (2022). SALL4: An Intriguing Therapeutic Target in Cancer Treatment. Cells. https://doi.org/10.3390/cells11162601
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.